Héctor A. Vaquera
@vaquerah-md.bsky.social
🇲🇽 Research fellow at Hematology Dept @uanl | Hematology. Lymphomas. Myeloma. HSCT.🩸🎗️
Reposted by Héctor A. Vaquera
Great to see another study w high efficacy of low-dose nivolumab (40mg Q2W; plus lenalidomide) in relapsed Hodgkin lymphoma: 90% ORR (60% CR, 30% PR), promising PFS & saturated PD1 receptor occupancy. Do we really need 240mg Q2W? www.sciencedirect.com/science/arti... @bloodjournals.hematology.org
November 13, 2025 at 8:36 PM
Great to see another study w high efficacy of low-dose nivolumab (40mg Q2W; plus lenalidomide) in relapsed Hodgkin lymphoma: 90% ORR (60% CR, 30% PR), promising PFS & saturated PD1 receptor occupancy. Do we really need 240mg Q2W? www.sciencedirect.com/science/arti... @bloodjournals.hematology.org
Reposted by Héctor A. Vaquera
Systematic review of low-dose anti-PD1 in Hodgkin lymphoma indicates comparable ORR, CR rates & toxicity to full dose aPD1 ascopubs.org/doi/10.1200/... Important open access publication @ascocancer.bsky.social JCO Global Oncology: Decrease costs and increase global health equity through aPD1 access?
May 23, 2025 at 6:19 AM
Systematic review of low-dose anti-PD1 in Hodgkin lymphoma indicates comparable ORR, CR rates & toxicity to full dose aPD1 ascopubs.org/doi/10.1200/... Important open access publication @ascocancer.bsky.social JCO Global Oncology: Decrease costs and increase global health equity through aPD1 access?
Happy to share our latest publication
For many in LMICs low-dose PD-1 blockers is the only way to afford this drugs and emergenig evidence suggests interesting things. Are we ready for more rigorous study of this intervention?
ascopubs.org/doi/10.1200/...
For many in LMICs low-dose PD-1 blockers is the only way to afford this drugs and emergenig evidence suggests interesting things. Are we ready for more rigorous study of this intervention?
ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
May 23, 2025 at 1:20 PM
Happy to share our latest publication
For many in LMICs low-dose PD-1 blockers is the only way to afford this drugs and emergenig evidence suggests interesting things. Are we ready for more rigorous study of this intervention?
ascopubs.org/doi/10.1200/...
For many in LMICs low-dose PD-1 blockers is the only way to afford this drugs and emergenig evidence suggests interesting things. Are we ready for more rigorous study of this intervention?
ascopubs.org/doi/10.1200/...
Results from the AQUILA trial #ASH24
A few thoughts:
- In absence of figures in uploaded abstracts, the n at risk table in the presentation is going to be important to pay attention to
- How many of such progression events were SLiM?
ash.confex.com/ash/2024/web...
A few thoughts:
- In absence of figures in uploaded abstracts, the n at risk table in the presentation is going to be important to pay attention to
- How many of such progression events were SLiM?
ash.confex.com/ash/2024/web...
Paper: Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
ash.confex.com
December 7, 2024 at 6:47 PM
Results from the AQUILA trial #ASH24
A few thoughts:
- In absence of figures in uploaded abstracts, the n at risk table in the presentation is going to be important to pay attention to
- How many of such progression events were SLiM?
ash.confex.com/ash/2024/web...
A few thoughts:
- In absence of figures in uploaded abstracts, the n at risk table in the presentation is going to be important to pay attention to
- How many of such progression events were SLiM?
ash.confex.com/ash/2024/web...
Reposted by Héctor A. Vaquera
Hung out with fellow @ash-hematology.bsky.social HONORS Alumnus @vaquerah-md.bsky.social & meet his classmate Rubi at ASH-a-Palooza! Learned so much about medical training in Mexico from these two. Watch out for these two amazing trainees who are changing the world! #ASHTrainee #ASHKudos #ASH24
December 7, 2024 at 3:09 PM
Hung out with fellow @ash-hematology.bsky.social HONORS Alumnus @vaquerah-md.bsky.social & meet his classmate Rubi at ASH-a-Palooza! Learned so much about medical training in Mexico from these two. Watch out for these two amazing trainees who are changing the world! #ASHTrainee #ASHKudos #ASH24
Reposted by Héctor A. Vaquera
Our study found that nearly 40% (!) of 12-21 yo females are iron deficient.
tinyurl.com/FeJAMA
But did you know that in addition to many physical symptoms, iron deficiency is associated with multiple mental health issues?
A #medsky #bluetorial 🧵1/
tinyurl.com/FeJAMA
But did you know that in addition to many physical symptoms, iron deficiency is associated with multiple mental health issues?
A #medsky #bluetorial 🧵1/
Prevalence of Iron Deficiency and Iron-Deficiency Anemia in US Females Aged 12-21 Years, 2003-2020
This study examines prevalence of iron deficiency among females aged 12 to 21 years to inform future screening strategies for iron deficiency and iron-deficiency anemia.
tinyurl.com
November 25, 2024 at 4:10 PM
Our study found that nearly 40% (!) of 12-21 yo females are iron deficient.
tinyurl.com/FeJAMA
But did you know that in addition to many physical symptoms, iron deficiency is associated with multiple mental health issues?
A #medsky #bluetorial 🧵1/
tinyurl.com/FeJAMA
But did you know that in addition to many physical symptoms, iron deficiency is associated with multiple mental health issues?
A #medsky #bluetorial 🧵1/
Reposted by Héctor A. Vaquera
🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼
PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼
A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼
doi.org/10.1182/bloo...
#MedSky #HemeSky
PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼
A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼
doi.org/10.1182/bloo...
#MedSky #HemeSky
November 21, 2024 at 4:38 PM
🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼
PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼
A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼
doi.org/10.1182/bloo...
#MedSky #HemeSky
PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼
A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼
doi.org/10.1182/bloo...
#MedSky #HemeSky
Check out our new work in Annals of Hematology:
✅ 73% ORR
✅ 43% CR
⚠️ 61% Grade 1-2 AE
✅ No Grade 3-4 AE
link.springer.com/article/10.1...
✅ 73% ORR
✅ 43% CR
⚠️ 61% Grade 1-2 AE
✅ No Grade 3-4 AE
link.springer.com/article/10.1...
Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory Hodgkin lymphoma - Annals of Hematology
Up to one-third of patients with classical Hodgkin lymphoma (cHL) are not responsive to first-line therapy or eventually relapse. Immune checkpoint inhibitors (ICIs) have been successfully employed to...
link.springer.com
November 25, 2024 at 2:31 PM
Check out our new work in Annals of Hematology:
✅ 73% ORR
✅ 43% CR
⚠️ 61% Grade 1-2 AE
✅ No Grade 3-4 AE
link.springer.com/article/10.1...
✅ 73% ORR
✅ 43% CR
⚠️ 61% Grade 1-2 AE
✅ No Grade 3-4 AE
link.springer.com/article/10.1...